Northern Trust Corp Boosts Stock Holdings in Fresenius Medical Care AG (NYSE:FMS)

Northern Trust Corp raised its stake in Fresenius Medical Care AG (NYSE:FMS - Free Report) by 45.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 362,190 shares of the company's stock after buying an additional 113,953 shares during the period. Northern Trust Corp owned 0.06% of Fresenius Medical Care worth $8,200,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Moran Wealth Management LLC grew its holdings in shares of Fresenius Medical Care by 9.1% during the fourth quarter. Moran Wealth Management LLC now owns 254,710 shares of the company's stock worth $5,767,000 after purchasing an additional 21,334 shares during the last quarter. ABC Arbitrage SA acquired a new stake in Fresenius Medical Care during the 4th quarter worth approximately $4,215,000. OLD Mission Capital LLC bought a new stake in Fresenius Medical Care during the 4th quarter worth approximately $3,545,000. Broyhill Asset Management bought a new stake in Fresenius Medical Care during the 4th quarter worth approximately $3,412,000. Finally, Marshall Wace LLP increased its position in Fresenius Medical Care by 128.0% in the 4th quarter. Marshall Wace LLP now owns 129,581 shares of the company's stock valued at $2,934,000 after acquiring an additional 72,740 shares during the period. Institutional investors own 8.37% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on FMS shares. Morgan Stanley reiterated an "underweight" rating on shares of Fresenius Medical Care in a report on Thursday, May 15th. Truist Financial lifted their target price on Fresenius Medical Care from $25.00 to $30.00 and gave the stock a "hold" rating in a report on Monday, May 12th. Finally, Wall Street Zen began coverage on Fresenius Medical Care in a research report on Tuesday. They issued a "strong-buy" rating on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $27.80.

Fresenius Medical Care Trading Down 1.7%

Shares of NYSE:FMS traded down $0.50 during trading on Thursday, reaching $29.30. The stock had a trading volume of 569,674 shares, compared to its average volume of 329,604. Fresenius Medical Care AG has a 52 week low of $17.93 and a 52 week high of $30.46. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. The firm's fifty day moving average is $25.33 and its 200 day moving average is $23.88. The stock has a market cap of $17.20 billion, a price-to-earnings ratio of 24.22, a P/E/G ratio of 0.76 and a beta of 0.85.

Fresenius Medical Care (NYSE:FMS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $0.44 EPS for the quarter, beating analysts' consensus estimates of $0.43 by $0.01. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%. The business had revenue of $5.54 billion for the quarter, compared to analysts' expectations of $4.71 billion. As a group, equities analysts forecast that Fresenius Medical Care AG will post 1.51 EPS for the current fiscal year.

Fresenius Medical Care Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 23rd will be paid a dividend of $0.7871 per share. The ex-dividend date of this dividend is Friday, May 23rd. This represents a yield of 1.9%. This is a boost from Fresenius Medical Care's previous annual dividend of $0.44. Fresenius Medical Care's dividend payout ratio (DPR) is currently 49.11%.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.